This result is like that observed for another competitive inhibitor to HSP90, NVP-BEB800, which reduces viability of cell lines in bulk, and primitive primary populations from B-ALL and also improves the survival of B-ALL in mice models [27]. Here, HSP90AB1 is linked to precursor B-cell acute lymphoblastic leukemia.